Dear Stakeholder:

We would like to inform you that Health Canada issued a one year extension to the section 56 exemption under the *Controlled Drugs and Substances Act* (CDSA) to exclude the substances listed below from the schedules of the CDSA and its regulations.

- Naloxegol and its salts
- Methylaltrexone and its salts
- Salts of Nalmefene
- Salts of Naloxone
- Salts of Naltrexone, and
- Barbituric acid *and its salts*

This section 56 exemption continues to effectively exempt the above named substances from the application of all provisions of the CDSA and its regulations. Please note that the salts of barbituric acid have been newly added to this section 56 exemption. Please find a copy of the exemption extension letter enclosed for your reference.

**What this means for stakeholders:**

While this section 56 exemption is in effect, individuals are not required to obtain a licence, register a test kit or obtain a section 56 exemption for the purpose of research to conduct activities with the above named substances. Also, individuals are not required to obtain a permit to import or export these substances to or from Canada.

Please note that it is the responsibility of the parties and individuals who work with a substance to be aware of the substance’s current status, and to meet any applicable regulatory requirements concerning them. If you are unsure if this section 56 exemption covers a specific substance, or are unsure of the status of any other substances please confirm its status by contacting: status@hc-sc.gc.ca

If you have any questions regarding this section 56 exemption, please do not hesitate to contact us at exemption@hc-sc.gc.ca or (613) 954-8246.

Sincerely,

Julie Thompson
Director
Office of Controlled Substances
Healthy Environments and Consumer Safety Branch
Health Canada